Heatwurx (NASDAQ:PCSA – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.19), Zacks reports.
Heatwurx Stock Performance
Shares of Heatwurx stock traded down $0.07 during midday trading on Friday, reaching $2.43. 49,930 shares of the company’s stock traded hands, compared to its average volume of 647,212. The stock has a 50 day moving average of $2.23 and a 200-day moving average of $2.50. Heatwurx has a 12 month low of $1.67 and a 12 month high of $14.24. The company has a market cap of $6.73 million, a PE ratio of -0.26 and a beta of 0.99.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heatwurx in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Heatwurx currently has an average rating of “Hold” and an average target price of $25.00.
Heatwurx Company Profile
Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.
Featured Stories
- Five stocks we like better than Heatwurx
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
Receive News & Ratings for Heatwurx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heatwurx and related companies with MarketBeat.com's FREE daily email newsletter.
